Bruker Corporation. (2/24/26). "Press Release: Bruker Expands Collaboration with Noetik to Advance Tissue Foundational Models for Translational and Therapeutic Applications". Orlando, FL.

	Organisation	Bruker Spatial Biology
	Group	Bruker (Group)
	Organisation 2	Noetik Inc.
	Product	artificial intelligence (AI) / machine learning (ML)
	Person	Munch, Mark R. (Bruker Corp 201407 President Bruker MAT Group before President Bruker Nano Surfaces Business)
	Person 2	Alfa, Ron A. (Noetik 202602 CEO + Co-Founder)

Bruker Spatial Biology, a division of Bruker Corporation (Nasdaq: BRKR) announced today that it will expand its collaboration with Noetik Inc., following their prior study of more than 3500 patient samples with the CosMx® Spatial Molecular Imager (SMI). CosMx SMI powers Noetik's pre-training and scaling of bio-foundation models to perform complex genome-wide simulations of human cellular- and tissue-level biology to enable diverse therapeutics applications.

“Noetik’s multiple spatial AI models, including the Oncology Counterfactual Therapeutics Oracle virtual cell, which can simulate patient biology and inform drug discovery, represent transformative breakthroughs for tackling human disease,” said Dr. Mark R. Munch, President of the Bruker NANO Group. To develop self-supervised AI, Noetik leverages the CosMx SMI platform to generate the largest and most biologically complete single-cell and subcellular spatial transcriptomic and multiomic datasets in oncology.

Noetik is now further imaging thousands of additional patients with the CosMx whole transcriptome assay to train their world models that learn from human tissue data.

“Spatial context is necessary for training foundation models that truly learn human biology. We have demonstrated that our models exhibit clear scaling laws; as we ingest more high-resolution CosMx data, we see a predictable and powerful increase in the models' ability to represent complex biology. We are excited to partner with Bruker to scale toward one billion spatially resolved human cells, spanning the breadth of oncology and beyond,” said Ron Alfa, MD, PhD, Co-Founder and CEO of Noetik.

This collaboration builds on Bruker’s best-in-class spatial biology portfolio, including CosMx SMI, AtoMx® SIP, CellScape™ XR, GeoMx® DSP and PaintScape™ platform, which together support high fidelity data generation for discovery and translational research.

Join Bruker at AGBT 2026

Bruker will share more details on recent advancements to CosMx SMI, alongside innovations across the entire Bruker Spatial Biology portfolio, at the AGBT hospitality suite in Dade Lounge throughout the week and in their Silver Sponsor Workshop on Wednesday, February 25.

For more information, please visit www.brukerspatialbiology.com.

About Bruker Corporation – Leader of the Post-Genomic Era

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

About Noetik

NOETIK is a frontier therapeutics company harnessing AI to deeply understand human biology and redefine clinical outcomes in oncology. Leveraging the largest proprietary multimodal oncology dataset of its kind, uniquely integrating spatial biology, NOETIK’s OCTO series of models (Oncology Counterfactual Therapeutics Oracle) precisely match therapeutic targets to patient subpopulations and accurately predict clinical efficacy. This AI-first approach elevates therapeutic development from probabilistic guesswork to precision science. By strategically partnering with clinical developers and in-licensing promising therapeutics, NOETIK accelerates the delivery of transformative cancer treatments to patients. To learn more about Noetik, visit https://www.noetik.ai.

Bruker Investor Contact:
Joe Kostka
Director, Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com

Bruker Media Contact:
Johnny Lyssand, PhD
Senior Director, Downstream Marketing
Bruker Spatial Biology
T: +1 (206) 790-2843
E: john.lyssand@bruker.com

Noetik Media Contact:
Thermal for Noetik
noetik@thermalpr.com

Record changed: 2026-03-04